Rabies Vaccine
Rabies
Rabies is caused by lyssavirus transmitted through the bite of an infected animal. Once clinical symptoms appear, rabies is virtually 100% fatal. It is one of the deadliest diseases known to medicine — only a handful of documented survivors of clinical rabies exist in medical literature. 59,000 people die of rabies annually, primarily in Asia and Africa, mostly from dog bites.
Overall Benefit Score
Default scenario · 12-month-old · US community (92% vax rate)
Score for your child →The risk-benefit balance in your specific scenario suggests a detailed conversation with your child's provider before deciding.
📊 Evidence Scores
Scores computed from peer-reviewed data using VaxFact's evidence model. Based on default scenario (12-month-old, standard US community).
🦠 Disease Burden
Rabies is caused by lyssavirus transmitted through the bite of an infected animal. Once clinical symptoms appear, rabies is virtually 100% fatal. It is one of the deadliest diseases known to medicine — only a handful of documented survivors of clinical rabies exist in medical literature. 59,000 people die of rabies annually, primarily in Asia and Africa, mostly from dog bites.
Clinical rabies causes encephalitis progressing to paralysis, hydrophobia (fear of water due to painful throat spasms), delirium, coma, and death within 2–10 days of symptom onset. It is considered one of the most terrifying deaths in medicine. Once started, there is essentially no treatment.
🛡️ Vaccine Effectiveness
Pre-exposure prophylaxis (PrEP): 3-dose series. Provides memory immunity allowing simplified post-exposure management. Titers should be checked every 2 years for high-risk individuals. Post-exposure: 100% effective if initiated before symptom onset. No known treatment failures with appropriately administered post-exposure prophylaxis.
No post-exposure prophylaxis failures have been documented in properly vaccinated and treated patients. Failures occur only when treatment is delayed or rabies immune globulin (RIG) is omitted.
⚠️ Adverse Events & Side Effects
All probabilities are per 100,000 doses administered, sourced from VAERS, Vaccine Safety Datalink, and post-licensure surveillance studies.
Common Side Effects
Rare Serious Events
📅 Vaccine Schedule
Pre-exposure vaccination is recommended for: travelers to countries where dog rabies is endemic (South/Southeast Asia, Central America, Africa), veterinarians and animal handlers, wildlife workers, spelunkers (bat exposure), laboratory workers with live virus. Titer testing every 2 years for ongoing risk.
⚖️ Benefits vs. Considerations
✓ Benefits
- 100% fatal disease — vaccination is the only prevention
- Pre-exposure vaccination eliminates the need for hard-to-obtain rabies immune globulin (RIG) in resource-limited settings after exposure
- Post-exposure prophylaxis is 100% effective if started before symptoms
- Simplifies post-exposure regimen for vaccinated individuals (2 doses vs 4 + RIG)
- Clean safety profile with 45 years of use
↕ Considerations
- 3-dose pre-exposure series is burdensome and expensive (~$500–1000 out of pocket in US)
- Requires periodic titer checks if ongoing high-risk exposure
- Immune complex reaction with HDCV boosters (~6%)
- Not warranted for most domestic US travelers — primarily for travel to Asia, Africa
🔬 What Some Researchers Question
These are legitimate scientific debates — not fringe claims. They represent areas of ongoing research or policy disagreement among credentialed experts.
- The 3-dose pre-exposure series costs $500–1,500 out of pocket in many US travel medicine clinics, making pre-exposure prophylaxis inaccessible to lower-income travelers who may be visiting higher-risk rural settings — creating a health equity problem where those at highest risk of serious animal bites (visiting family in rural South Asia) are least able to afford pre-exposure vaccination.
🌫️ Scientific Uncertainties
Honest acknowledgment of what we don't yet know with confidence.
- Optimal timing and frequency of booster doses for high-risk individuals (titer-based vs. time-based)
- Whether 2-dose pre-exposure schedules are equivalent to 3-dose — some countries are evaluating this
🌍 International Policy Comparison
How different countries approach this vaccine — revealing where global consensus is strong vs. where policy diverges.